Dr. Victor Velculescu, CEO and founder of Delfi Diagnostics. Baltimore life sciences company Delfi Diagnostics is $225 million closer to bringing its blood test for early detection of cancer to the ...

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who ...

It didn’t take Delfi Diagnostics long after its 2019 founding to hit the coveted nine-digit funding mark: It reached that milestone in early 2021 with the close of its $100 million series A. Less than ...

BALTIMORE and PALO ALTO, Calif., April 25, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer ...

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the ...

MANILA, Philippines - After conquering the world market for chocolate products, Delfi, a top chocolate confectionery brand, is set to make ripples in the country as it brings its world class-quality ...

DELFI-Tumor Fraction assay was developed to improve noninvasive assessment of tumor burden and monitoring of treatment efficacy and resistance in patients with advanced cancers. DELFI Diagnostics ...

These days, cancer-spotting liquid biopsy offerings are a dime a dozen, with everyone from Grail to Guardant throwing their hats in the ring and cancer-screening blood test developers making up three ...

The Remington-based startup was founded by Johns Hopkins oncology professor Dr. Victor Velculescu, who also cofounded Canton’s Personal Genome Diagnostics. Inside FastForward 1812, an East ...

If you want to know who really controls Delfi Limited (SGX:P34), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company ...

From the San Francisco Business Times. Liquid biopsy is a crowded market, particularly in the Bay Area, where a number of startups have grown into billion-dollar enterprises like Grail, Freenome and ...

NEW YORK--(BUSINESS WIRE)--Delfi, a machine-learning risk management platform for financial institutions, has partnered with three U.S. banks to revolutionize interest rate risk management.